Gene therapy treatment Luxturna accepted for use in Scotland
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
Search
Search results
A fond farewell and a warm welcome
After more than 10 years of service as Chair of the Board of Trustees, Don Grocott has retired.
Taking on The Thames Path Challenge
Next month, Anisha and Sheena will take on The Thames Path Challenge. Together, they explain why they decided to join #TeamRetinaUK.
Meet our supporters: Ian Shorthose
Whether you're an expert runner, or a rebel *with* a cause, there's no better experience than the London Marathon!
Webinar: Fitness, blisters and fundraising
Have you ever been tempted to take part in the TCS London Marathon? In 2022 the TCS London Marathon raised £58.3 million for charity so it’s a vital source of income.
Types of genetic testing
This page explains the different types of genetic tests: diagnostic testing, predictive testing, carrier testing and research testing
Autoimmune Retinopathy
Autoimmune diseases are quite distinct from inherited retinal dystrophies.
Exciting developments for new treatment research
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
Medical research
Retina UK has invested more than £16million into cutting-edge research since the charity was founded in 1976.
Meet a Researcher: Elena Piotter
Nurturing a new generation of scientists is a vital investment in the future of retinal disease research, so we are delighted to be funding, in collaboration with the Macular Society, a new PhD studentship at Oxford University, supervised by Professor Robert MacLaren.